Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)	Apr. 03, 2016
Operating Segments [Member] | Developed Technology Rights [Member] | Global Innovative Pharmaceutical [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	21.00%
Operating Segments [Member] | Developed Technology Rights [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	29.00%
Operating Segments [Member] | Developed Technology Rights [Member] | Global Established Pharmaceutical [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	50.00%
Operating Segments [Member] | Brands [Member] | Global Innovative Pharmaceutical [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Operating Segments [Member] | Brands [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	73.00%
Operating Segments [Member] | Brands [Member] | Global Established Pharmaceutical [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	27.00%
Research and Development Expense [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Research and Development Expense [Member] | Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%